MAP was found to be methodologically robust when utilized i) to detect EGFR mutations in lung tissue; ii) to detect p53 breast cancer signatures in plasma and the cellular compartments of blood; or iii) to screen for mosaicism for common EGFR mutations in a large population. The gene discussed is EGFR; the disease is breast cancer.